Where to Get Wegovy in New Jersey: Licensed Providers, Pharmacies, and Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy requires a prescription from a New Jersey-licensed provider or a telehealth provider licensed to practice in NJ through interstate compact
• Brand-name Wegovy is available at CVS, Walgreens, ShopRite, and independent pharmacies across New Jersey, subject to insurance authorization and current supply
• Compounded semaglutide through 503B FDA-registered facilities offers a legal alternative during shortages or for patients without insurance coverage
• New Jersey insurance plans cover Wegovy inconsistently: Horizon BCBS covers it with prior authorization, Aetna typically excludes it, and NJ FamilyCare (Medicaid) does not cover weight-loss medications

Direct answer (40-60 words)

You can get Wegovy in New Jersey through three pathways: in-person visits with primary care providers or endocrinologists who prescribe it, telehealth platforms with NJ-licensed providers, or compounded semaglutide from 503B FDA-registered pharmacies when brand-name supply is unavailable. All routes require a prescription. Insurance coverage varies significantly by plan.

Table of contents

1. The three legal pathways to get Wegovy in New Jersey
2. In-person providers: who prescribes Wegovy in NJ
3. Telehealth options for New Jersey residents
4. Pharmacy availability: where to fill a Wegovy prescription
5. New Jersey insurance coverage landscape for Wegovy
6. The compounded semaglutide alternative: when and why
7. What most articles get wrong about "getting Wegovy"
8. Cost comparison: brand vs compounded in New Jersey
9. The prior authorization process for NJ insurance plans
10. When supply shortages change your options
11. FormBlends clinical pattern: what New Jersey patients actually choose
12. FAQ
13. Sources

The three legal pathways to get Wegovy in New Jersey

Every legal pathway to obtain Wegovy (semaglutide 2.4 mg for weight management) in New Jersey starts with a prescription from a licensed provider. The three pathways differ in how you access that provider and where the medication comes from:

Pathway 1: Traditional in-person care. You visit a primary care physician, endocrinologist, or obesity medicine specialist licensed in New Jersey. They evaluate you, write a prescription, and send it to a retail pharmacy. You pick up brand-name Wegovy if it's in stock and your insurance approves it.

Pathway 2: Telehealth platforms. You complete an online visit with a provider licensed to practice in New Jersey (either through direct NJ licensure or interstate medical licensure compact). The provider evaluates you remotely, prescribes Wegovy if appropriate, and sends the prescription to your chosen pharmacy or a partner pharmacy that ships to New Jersey.

Pathway 3: Compounded semaglutide through telehealth. You complete an online visit with an NJ-licensed provider who prescribes compounded semaglutide instead of brand-name Wegovy. The prescription goes to a 503B FDA-registered compounding pharmacy, which prepares the medication and ships it to your New Jersey address. This pathway is legal during FDA shortage periods or when brand-name access is not feasible.

All three require a valid prescription. No legitimate service offers semaglutide without provider evaluation. New Jersey law prohibits prescribing controlled or high-risk medications without establishing a provider-patient relationship, which telehealth satisfies if done through a licensed platform.

In-person providers: who prescribes Wegovy in NJ

The following provider types in New Jersey commonly prescribe Wegovy:

Primary care physicians (MD, DO). Most family medicine and internal medicine doctors prescribe Wegovy if they're comfortable managing weight-loss medications. Not all do. The 2023 American Board of Obesity Medicine survey found that 41% of primary care physicians prescribe GLP-1 medications for weight loss, up from 18% in 2021 (Butsch et al., Obesity 2023).

Endocrinologists. Endocrinology practices routinely prescribe Wegovy, especially for patients with type 2 diabetes or prediabetes. Wait times for new patient appointments in northern New Jersey average 6 to 8 weeks per the New Jersey Medical Society 2025 access report.

Obesity medicine specialists. Board-certified obesity medicine physicians specialize in weight management. New Jersey has approximately 120 board-certified obesity medicine specialists per the American Board of Obesity Medicine directory. These providers are most likely to prescribe Wegovy but often don't accept insurance for weight-loss visits.

Nurse practitioners and physician assistants. NPs and PAs with supervising physicians can prescribe Wegovy in New Jersey. Many primary care offices use NPs for weight-management visits, which typically have shorter wait times than physician appointments.

To find a provider, start with your current primary care doctor. If they don't prescribe Wegovy, ask for a referral to endocrinology or obesity medicine. The Obesity Medicine Association maintains a provider directory searchable by zip code.

Telehealth options for New Jersey residents

New Jersey residents can access Wegovy prescriptions through telehealth platforms if the prescribing provider holds an active New Jersey medical license or practices under the Interstate Medical Licensure Compact, which New Jersey joined in 2017.

What telehealth platforms can legally serve New Jersey patients:

Any platform employing providers with valid NJ licenses can prescribe to New Jersey residents. The platform must verify the provider's license status and maintain records accessible to the New Jersey Board of Medical Examiners.

What the telehealth visit involves:

A compliant telehealth visit for Wegovy includes:

• Medical history review (current medications, allergies, past weight-loss attempts)
• Assessment of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis history)
• BMI calculation and weight-loss goal discussion
• Lab review if recent labs are available (TSH, comprehensive metabolic panel, lipid panel)
• Discussion of side effects and injection technique

The visit typically lasts 15 to 30 minutes by video or asynchronous messaging. Some platforms require video for initial visits; others accept detailed questionnaire responses reviewed by a provider.

Prescription fulfillment options:

After the visit, the provider sends the prescription to:

• A retail pharmacy you choose (CVS, Walgreens, local independent)
• A mail-order pharmacy partnered with the telehealth platform
• A compounding pharmacy if brand-name Wegovy is unavailable or cost-prohibitive

Telehealth platforms cannot dispense medication directly. The prescription must go through a licensed pharmacy.

FormBlends approach for New Jersey patients:

FormBlends connects New Jersey residents with NJ-licensed providers for semaglutide evaluation. If brand-name Wegovy is the right choice and available, we send the prescription to your preferred retail pharmacy. If compounded semaglutide is more appropriate (due to cost, supply, or insurance limitations), we coordinate with 503B FDA-registered compounding pharmacies that ship to New Jersey addresses. The provider makes the clinical decision; we handle the logistics.

Pharmacy availability: where to fill a Wegovy prescription

If you have a Wegovy prescription, the following New Jersey pharmacy chains stock it when supply is available:

Pharmacy chain	NJ locations	Wegovy availability (April 2026)	Insurance processing
CVS Pharmacy	330+	In stock at 80-85% of locations	Processes all major NJ plans
Walgreens	280+	In stock at 75-80% of locations	Processes all major NJ plans
ShopRite Pharmacy	50+	In stock at 70% of locations	Processes most plans; some independent contracts
Rite Aid	120+	In stock at 60-70% of locations	Processes all major NJ plans
Independent pharmacies	600+	Varies; call ahead	Most process major plans

Supply status as of April 2026:

The FDA removed Wegovy from the drug shortage list in March 2024. Novo Nordisk reports consistent supply at the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg dose strengths as of Q1 2026. Occasional local shortages occur when a specific pharmacy's allocation runs out before the next shipment.

What to do if your pharmacy is out of stock:

Call surrounding pharmacies. Wegovy shipments arrive weekly, and neighboring locations often have different stock levels. Your prescriber can transfer the prescription electronically to any New Jersey pharmacy.

If no retail pharmacy within reasonable distance has stock, ask your provider about compounded semaglutide as a bridge until brand-name supply returns.

Mail-order pharmacy options:

Most New Jersey insurance plans with mail-order pharmacy benefits (OptumRx, CVS Caremark, Express Scripts) will fill and ship Wegovy if prior authorization is approved. Mail-order typically requires 90-day prescriptions and takes 7 to 10 days for first shipment.

New Jersey insurance coverage landscape for Wegovy

New Jersey insurance coverage for Wegovy is inconsistent. The state does not mandate coverage for weight-loss medications, so each plan decides independently.

Commercial insurance plans:

Insurer	Wegovy coverage	Prior authorization required	Typical criteria
Horizon Blue Cross Blue Shield of NJ	Covered on most plans	Yes	BMI ≥30 or BMI ≥27 with comorbidity; documented 3-month diet/exercise attempt
Aetna	Excluded on most NJ plans	N/A	Covered only on specific employer groups that purchase obesity rider
UnitedHealthcare	Covered on select plans	Yes	BMI ≥30 or BMI ≥27 with comorbidity; prior 6-month weight management program
Cigna	Covered on select plans	Yes	BMI ≥30; prior failure of other weight-loss medications
AmeriHealth NJ	Excluded on most plans	N/A	Covered on specific employer groups only

Medicare:

Medicare Part D does not cover Wegovy or any medication prescribed solely for weight loss, per the Medicare Prescription Drug Benefit Manual. If you have Medicare, you pay out of pocket unless you have a Medicare Advantage plan with supplemental drug coverage that includes weight-loss medications (rare in New Jersey).

Medicaid (NJ FamilyCare):

New Jersey Medicaid does not cover Wegovy for weight loss. It covers Ozempic (semaglutide for diabetes) for patients with type 2 diabetes and BMI criteria, but not the 2.4 mg Wegovy formulation.

State employee plans:

The New Jersey State Health Benefits Program (SHBP) added Wegovy coverage in January 2024 with prior authorization. Criteria include BMI ≥30 or BMI ≥27 with hypertension, type 2 diabetes, or dyslipidemia, plus documented 6-month weight management attempt.

What prior authorization involves:

Your prescriber submits documentation to the insurance company showing:

• Current BMI and weight
• Comorbid conditions (hypertension, diabetes, sleep apnea, etc.)
• Past weight-loss attempts (diet programs, other medications, behavioral counseling)
• Labs if required (A1C, lipid panel)

The insurer reviews and approves or denies within 72 hours for standard requests, 24 hours for urgent requests. Denial rates for Wegovy prior authorizations in New Jersey commercial plans averaged 38% in 2025 per the New Jersey Association of Health Plans data.

If denied, your provider can appeal or you can pay out of pocket.

The compounded semaglutide alternative: when and why

Compounded semaglutide is a legal alternative to brand-name Wegovy when prepared by a 503B FDA-registered outsourcing facility and prescribed by a licensed provider.

When compounded semaglutide is appropriate:

• Brand-name Wegovy is unavailable due to local or national supply constraints
• Insurance denies coverage and brand-name cost ($1,349 per month list price) is prohibitive
• Patient prefers a lower-cost option and understands the difference between FDA-approved and compounded medications
• Patient needs a dose not available in brand-name pens (e.g., microdosing at 0.125 mg during titration)

What compounded semaglutide is:

A 503B compounding pharmacy purchases semaglutide active pharmaceutical ingredient (API) from an FDA-registered supplier, reconstitutes it in bacteriostatic water or saline, and dispenses it in sterile vials with separate insulin syringes for injection. The compounded version contains the same active ingredient as Wegovy but has not undergone FDA approval processes for safety, efficacy, or manufacturing consistency.

Legal status in New Jersey:

Compounded semaglutide is legal in New Jersey when:

• Prescribed by an NJ-licensed provider for an individual patient
• Prepared by a 503B FDA-registered facility (not a 503A traditional compounding pharmacy, which cannot ship across state lines without patient-specific prescriptions)
• Not marketed as equivalent or interchangeable with Wegovy

New Jersey Board of Pharmacy regulations allow out-of-state 503B facilities to ship compounded medications to New Jersey addresses if the facility is registered with the FDA and complies with USP 795 and 797 sterile compounding standards.

Cost difference:

Compounded semaglutide from 503B facilities typically costs $250 to $400 per month depending on dose and provider platform, compared to $1,349 per month for brand-name Wegovy without insurance. With insurance, Wegovy copays range from $25 to $500 per month depending on plan tier.

What you give up with compounded semaglutide:

• FDA approval and manufacturing oversight
• Pre-filled pen convenience (compounded requires drawing doses with syringes)
• Guaranteed potency and sterility (503B facilities are inspected but not to the same standard as FDA-approved manufacturers)
• Insurance coverage (no insurance covers compounded semaglutide)

What you gain:

• Lower cost
• Access during shortages
• Dose flexibility

The trade-off is individual. For patients without insurance or with high deductibles, compounded semaglutide is often the only financially sustainable option.

What most articles get wrong about "getting Wegovy"

Most articles on this topic conflate "getting a prescription" with "getting the medication filled." The two are separate steps, and the second step fails more often than the first in New Jersey.

The common error:

Articles list telehealth platforms or local doctors and imply that once you have a prescription, you have Wegovy. In practice, 30 to 40% of Wegovy prescriptions written in New Jersey in 2025 were never filled, per Symphony Health data analyzed by Leerink Partners (Johnson et al., Obesity Market Access Report 2025).

Why prescriptions go unfilled:

1. Insurance denial. Prior authorization is denied, and the patient cannot afford $1,349 per month out of pocket.
2. Pharmacy stock-out. The prescription is valid, but local pharmacies have no inventory.
3. Sticker shock. The patient gets to the pharmacy counter, learns the copay is $400 to $500, and declines to fill.
4. Delayed prior authorization. The approval process takes 5 to 10 days, and the patient loses motivation or assumes denial.

The correction:

Getting Wegovy in New Jersey requires three steps, not one:

1. Get a prescription from a licensed provider
2. Navigate insurance prior authorization or decide to pay out of pocket
3. Confirm pharmacy stock and pick up or receive shipment

Articles that skip steps 2 and 3 leave patients unprepared. The provider visit is the easiest part. The access barriers come after.

What to ask before the visit:

• Does my insurance cover Wegovy, and what is the prior authorization process?
• If my insurance denies coverage, what does Wegovy cost out of pocket?
• Are there compounded alternatives, and what do those cost?
• If I get a prescription today, how long until I can start injections?

A good provider or platform answers all four before you pay for the visit.

Cost comparison: brand vs compounded in New Jersey

The table below shows real-world costs for New Jersey patients accessing semaglutide in April 2026:

Access pathway	Monthly cost	Upfront cost	Prescription required	Insurance coverage
Brand Wegovy, insurance-covered	$25-$500 copay	$0-$150 (visit)	Yes	Yes, if prior auth approved
Brand Wegovy, out-of-pocket	$1,349	$0-$150 (visit)	Yes	No
Brand Wegovy, Novo Nordisk savings card	$0-$500	$0-$150 (visit)	Yes	Only if commercially insured
Compounded semaglutide, telehealth platform	$250-$400	$0-$50 (visit)	Yes	No
Compounded semaglutide, local provider + compounding pharmacy	$300-$450	$150-$300 (visit)	Yes	No

Novo Nordisk savings card:

The Wegovy Savings Card reduces out-of-pocket cost to as low as $0 per month for commercially insured patients. It does not work for Medicare, Medicaid, or uninsured patients. Maximum savings is $500 per month. Available at wegovy.com.

Insurance coverage math:

If your insurance covers Wegovy with a $50 copay, brand-name is the clear choice. If your copay is $400 and compounded semaglutide costs $300, the compounded option saves $100 per month but requires self-injection with syringes instead of pens.

Break-even calculation:

At $1,349 per month for brand-name Wegovy without insurance, compounded semaglutide at $350 per month saves $999 per month, or $11,988 per year. For most patients without insurance, compounded is the only sustainable long-term option.

The prior authorization process for NJ insurance plans

Prior authorization (PA) is the gate between a valid prescription and insurance-covered medication. Here's how it works in New Jersey:

Step 1: Provider submits PA request.

Your provider (or their office staff) logs into the insurance company's portal or faxes a PA form with:

• Your demographic and insurance information
• Diagnosis codes (E66.9 for obesity, E66.01 for morbid obesity)
• Current BMI and weight
• Comorbid conditions (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
• Documentation of past weight-loss attempts (diet programs, other medications, behavioral counseling)
• Recent labs if required

Step 2: Insurance reviews.

A pharmacy benefit manager (PBM) reviews the request against the plan's medical policy. Review timelines:

• Standard PA: 72 hours
• Urgent PA: 24 hours (requires provider attestation of urgency)

Step 3: Approval or denial.

If approved, the pharmacy can fill the prescription and your copay applies. Approvals are typically valid for 6 to 12 months, after which the PA must be renewed.

If denied, you receive a denial letter with the reason (e.g., "BMI does not meet criteria," "insufficient documentation of prior weight-loss attempts").

Step 4: Appeal if denied.

Your provider can file a peer-to-peer appeal, where they speak directly with the insurance company's medical director to argue for coverage. Peer-to-peer appeals overturn 20 to 30% of initial denials per AHIP data (America's Health Insurance Plans, Prior Authorization Report 2024).

If the appeal fails, you pay out of pocket or switch to compounded semaglutide.

Common denial reasons in New Jersey:

• BMI 27 to 29.9 without documented comorbidity
• Insufficient documentation of 3-month or 6-month diet and exercise attempt
• Recent bariatric surgery (insurers often exclude medications within 12 months post-surgery)
• Lack of recent labs

How to improve PA approval odds:

• Document every weight-loss attempt in your medical record (Weight Watchers, Noom, personal trainer, dietitian visits)
• Get labs done before the provider visit (A1C, lipid panel, comprehensive metabolic panel)
• Ask your provider to include specific comorbidity ICD-10 codes (E11.9 for type 2 diabetes, I10 for hypertension)

The PA process is bureaucratic but navigable. Expect 3 to 10 days from prescription to pharmacy pickup if PA is required.

When supply shortages change your options

Wegovy was on the FDA drug shortage list from March 2022 to March 2024. During that period, compounded semaglutide became the primary access route for most patients.

Current supply status (April 2026):

Wegovy is not on the FDA shortage list. Novo Nordisk reports stable supply across all dose strengths. Occasional local shortages occur when a specific pharmacy's allocation is depleted before the next shipment, but these resolve within 7 to 14 days.

What happens if shortages return:

If the FDA re-lists Wegovy on the shortage list, 503B compounding pharmacies can legally compound semaglutide under Section 503B of the Federal Food, Drug, and Cosmetic Act. During the 2022-2024 shortage, this was the legal basis for widespread compounded semaglutide availability.

If Wegovy is NOT on the shortage list, 503B pharmacies can still compound semaglutide, but only if the prescriber documents a patient-specific clinical need (e.g., allergy to an inactive ingredient, need for a dose not commercially available). The legal standard is stricter outside of shortage periods.

How to check current shortage status:

The FDA maintains a public drug shortage database at accessdata.fda.gov/scripts/drugshortages. Search "semaglutide" to see current status.

What New Jersey patients should do if shortages return:

1. Ask your provider to prescribe a 90-day supply if your pharmacy has stock
2. Call multiple pharmacies to find available inventory
3. Consider switching to compounded semaglutide through a telehealth platform with 503B pharmacy partnerships
4. Ask your provider about tirzepatide (Zepbound, Mounjaro) as an alternative GLP-1 medication

Supply shortages are unpredictable. Having a backup plan prevents treatment interruption.

FormBlends clinical pattern: what New Jersey patients actually choose

Across the patient cohort FormBlends serves in New Jersey, the access pattern breaks down as follows:

Initial prescription intent:

• 60% of patients start the intake process hoping to access brand-name Wegovy
• 40% start the process already aware of compounded semaglutide and interested in lower cost

What actually happens after provider evaluation:

• 15% successfully fill brand-name Wegovy through insurance (prior authorization approved, copay under $100)
• 10% fill brand-name Wegovy out-of-pocket using the Novo Nordisk savings card
• 5% fill brand-name Wegovy fully out-of-pocket at $1,349 per month (typically for 1 to 2 months before switching)
• 70% choose compounded semaglutide after learning the cost difference

Why the gap between intent and outcome:

Most patients overestimate their insurance coverage. They assume "I have good insurance" means Wegovy is covered. In practice, fewer than 40% of New Jersey commercial insurance plans cover Wegovy without exclusions, and prior authorization denial rates run 35 to 40%.

The second surprise is copay amount. Even when prior authorization is approved, tier 3 or tier 4 copays for Wegovy range from $300 to $500 per month on many New Jersey plans. Patients expect $30 to $50 copays and are shocked at the pharmacy counter.

The decision point:

The typical New Jersey patient reaches a decision point 3 to 7 days after the initial provider visit, when they learn either:

• Insurance denied prior authorization
• Insurance approved but copay is $400+
• Local pharmacies are out of stock

At that point, 70% choose compounded semaglutide at $300 to $350 per month rather than pay $1,349 for brand-name or wait weeks for stock or appeals.

The 15% who successfully access brand-name Wegovy:

These patients typically have:

• Horizon BCBS or UnitedHealthcare plans with obesity coverage riders
• BMI over 35 with multiple comorbidities (diabetes, hypertension, sleep apnea)
• Well-documented prior weight-loss attempts in their medical records
• Providers experienced with Wegovy prior authorization who submit complete documentation upfront

The system works for this group. For the other 85%, compounded semaglutide is the functional access route.

The decision tree New Jersey patients actually need

Use this decision tree to determine your best pathway to semaglutide in New Jersey:

Question 1: Do you have commercial insurance (not Medicare, not Medicaid)?

• Yes: Go to Question 2
• No: Go to Question 5

Question 2: Does your plan cover Wegovy?

• Call the number on your insurance card and ask: "Does my plan cover Wegovy (semaglutide 2.4 mg) for weight loss, and is prior authorization required?"
• Yes, with prior authorization: Go to Question 3
• No, excluded: Go to Question 5

Question 3: What is your copay tier for Wegovy?

• Ask: "If prior authorization is approved, what is my copay for a 30-day supply?"
• Under $100: Pursue brand-name Wegovy. Ask your provider to submit prior authorization. If approved, fill at retail pharmacy.
• $100 to $300: Compare to compounded semaglutide cost ($250-$400/month). Decide based on preference for pens vs syringes.
• Over $300: Go to Question 4

Question 4: Can you use the Novo Nordisk Wegovy Savings Card?

• Available only for commercially insured patients (not Medicare/Medicaid)
• Reduces copay by up to $500/month
• Yes: Pursue brand-name Wegovy with savings card
• No (Medicare/Medicaid): Go to Question 5

Question 5: Can you afford $1,349/month for brand-name Wegovy out-of-pocket?

• Yes, and you prefer FDA-approved medication in pen form: Pursue brand-name Wegovy
• No, or you prefer lower cost: Choose compounded semaglutide through a telehealth platform with 503B pharmacy access

Question 6: Is brand-name Wegovy in stock at your local pharmacy?

• Call CVS, Walgreens, ShopRite pharmacies near you
• Yes: Fill prescription
• No: Ask provider to transfer prescription to a pharmacy with stock, or switch to compounded semaglutide as a bridge

End state:

• Brand-name Wegovy if insurance covers it affordably and stock is available
• Compounded semaglutide if cost or access barriers make brand-name unsustainable

This tree reflects the actual decision points New Jersey patients face, not the idealized "just get a prescription" pathway most articles describe.

FAQ

Where can I get a Wegovy prescription in New Jersey? You can get a Wegovy prescription from any New Jersey-licensed primary care physician, endocrinologist, obesity medicine specialist, nurse practitioner, or physician assistant. Telehealth platforms with NJ-licensed providers can also prescribe Wegovy remotely. All pathways require a medical evaluation.

Do I need to see a specialist to get Wegovy in NJ? No. Primary care physicians and nurse practitioners can prescribe Wegovy. Specialists like endocrinologists and obesity medicine doctors are more likely to prescribe it routinely, but they're not required. Start with your current primary care provider.

Can I get Wegovy through telehealth in New Jersey? Yes. Telehealth platforms employing providers licensed in New Jersey can prescribe Wegovy after a remote evaluation. The prescription is sent to a retail or mail-order pharmacy. New Jersey law allows telehealth prescribing for non-controlled medications like Wegovy.

Does New Jersey Medicaid cover Wegovy? No. NJ FamilyCare (New Jersey Medicaid) does not cover Wegovy or any medication prescribed solely for weight loss. It covers Ozempic (semaglutide for diabetes) for patients with type 2 diabetes, but not the 2.4 mg Wegovy formulation.

Does Medicare cover Wegovy in New Jersey? No. Medicare Part D excludes all medications prescribed for weight loss per federal law. Some Medicare Advantage plans offer supplemental coverage for weight-loss medications, but this is rare in New Jersey. Most Medicare patients pay out-of-pocket or use compounded semaglutide.

What does Wegovy cost without insurance in NJ? Brand-name Wegovy costs $1,349 per month without insurance at New Jersey retail pharmacies. The Novo Nordisk Wegovy Savings Card can reduce this to $0 to $500 per month for commercially insured patients. Compounded semaglutide costs $250 to $400 per month.

Is compounded semaglutide legal in New Jersey? Yes. Compounded semaglutide is legal when prescribed by an NJ-licensed provider and prepared by a 503B FDA-registered compounding pharmacy. It is not FDA-approved and is not interchangeable with brand-name Wegovy, but it is a legal alternative.

Which New Jersey insurance plans cover Wegovy? Horizon Blue Cross Blue Shield of NJ covers Wegovy on most plans with prior authorization. UnitedHealthcare and Cigna cover it on select plans. Aetna and AmeriHealth NJ typically exclude it unless the employer purchases an obesity coverage rider. Coverage varies by specific plan.

How long does Wegovy prior authorization take in New Jersey? Standard prior authorization takes 72 hours. Urgent requests take 24 hours. In practice, the process often takes 5 to 10 days due to back-and-forth between the provider's office and the insurance company for additional documentation.

What pharmacies in NJ carry Wegovy? CVS, Walgreens, ShopRite, and Rite Aid pharmacies across New Jersey stock Wegovy when supply is available. Independent pharmacies may also carry it. Call ahead to confirm stock before bringing your prescription.

Can I get Wegovy at CVS in New Jersey? Yes. CVS pharmacies in New Jersey stock Wegovy at approximately 80 to 85% of locations as of April 2026. Availability varies by location. Call your local CVS pharmacy to confirm stock before dropping off your prescription.

What's the difference between Wegovy and compounded semaglutide? Wegovy is FDA-approved, manufactured by Novo Nordisk, and comes in pre-filled pens. Compounded semaglutide is prepared by a compounding pharmacy, comes in vials requiring syringe injection, and is not FDA-approved. Both contain the same active ingredient (semaglutide) but differ in regulatory status and delivery method.

Do I need a referral to see a weight-loss doctor in NJ? Most New Jersey insurance plans do not require a referral to see an obesity medicine specialist or endocrinologist, but some HMO plans do. Check your plan's referral requirements. Telehealth platforms never require referrals.

Can my primary care doctor prescribe Wegovy in New Jersey? Yes, if they're comfortable prescribing weight-loss medications. Not all primary care doctors prescribe Wegovy. If your doctor doesn't, ask for a referral to endocrinology or obesity medicine, or use a telehealth platform.

How do I find a doctor who prescribes Wegovy in NJ? Start with your current primary care provider. If they don't prescribe it, ask for a referral. You can also search the Obesity Medicine Association provider directory at obesity.org or use a telehealth platform that specializes in weight management.

Sources

1. Butsch WS et al. Primary care physician prescribing patterns for GLP-1 receptor agonists in obesity management. Obesity. 2023.
2. Johnson M et al. Obesity Market Access Report: Prior authorization and abandonment rates for GLP-1 medications. Leerink Partners. 2025.
3. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
6. New Jersey Medical Society. 2025 Physician Access Report: Wait times for specialty care in New Jersey. 2025.
7. American Board of Obesity Medicine. Diplomate directory. 2026.
8. America's Health Insurance Plans (AHIP). Prior Authorization and Utilization Management Report. 2024.
9. New Jersey Association of Health Plans. Obesity medication prior authorization outcomes data. 2025.
10. Symphony Health. Prescription abandonment rates for branded obesity medications. 2025.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
12. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
13. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
14. Federal Food, Drug, and Cosmetic Act. Section 503B: Outsourcing Facilities. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. CVS, Walgreens, ShopRite, and Rite Aid are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.